CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Operating expenses:
Research and development	$ 38,761	$ 22,173	$ 13,516
General and administrative	17,437	8,773	5,713
Total operating expenses	56,198	30,946	19,229
Loss from operations	(56,198)	(30,946)	(19,229)
Other income (expense):
Research and development incentives	3,084	2,528	2,267
Investment income	2,424	2,585	288
Interest expense on finance lease liability	(1,185)
Interest expense on debt obligations	(734)
Change in fair value of warrant liability		(5,452)	(972)
Other income (expense)	(16)	451	(2,056)
Total other income (expense), net	3,573	112	(473)
Net loss attributable to common stockholders	$ (52,625)	$ (30,834)	$ (19,702)
Net loss per share attributable to common shareholders, basic and diluted (in dollars per share)	$ (1.54)	$ (1.33)	$ (3.96)
Weighted average common shares outstanding-basic and diluted (in shares)	34,261,548	23,198,400	4,978,539